Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi has announced the discontinuation of its Phase 3 MOBILIZE study evaluating…
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
Antag Therapeutics has appointed obesity treatment expert Philip Just Larsen as Chief…
Sanofi joins regional push to raise Rare Disease awareness
Sanofi has partnered with the UAE Rare Disease Society and the Saudi…
New Evidence Suggests One RSV Immunization May Protect Babies for Two Years
A landmark study from Spain shows that a single RSV immunization with…
EU Approves Sanofiโs Teizeild to Delay Onset of Type 1 Diabetes in Adults and Children
The European Commission has approved Teizeild, the first disease-modifying therapy for type…
Sanofi to acquire Dynavax
Sanofi has announced an agreement to acquire Dynavax Technologies Corporation, a publicly…
MoHAP-UAE signs MoU with Sanofi to strengthen efforts to prevent Chronic Respiratory Diseases and combat Tobacco Use
The Ministry of Health and Prevention (MoHAP) has signed a Memorandum of…
Sanofi Completes Acquisition of Blueprint Medicines
Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint),…
Sanofiโs SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
The US Food and Drug Administration (FDA) has granted fast track designation…
Abu Dhabi Concludes Fourth Consecutive U.S. Mission Further Reinforcing Global Healthcare Leadership
Abu Dhabi has further solidified its position as the MENA regionโs premier…
